SPIA
TRIL

Steward Partners Investment Advisory’s Trillium Therapeutics Inc. TRIL Stock Holding History

Steward Partners Investment Advisory’s Portfolio TRIL Stock Details TRIL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-2,500
Closed -$24K – 3441
2021
Q2 		$24K Sell
2,500
-7,900
-76% -$74.3K ﹤0.01% 4875
2021
Q1 		$112K Buy
10,400
+1,800
+21% +$22.3K ﹤0.01% 1562
2020
Q4 		$127K Buy
8,600
+900
+12% +$13K ﹤0.01% 1271
2020
Q3 		$109K Buy
7,700
+500
+7% +$4.99K ﹤0.01% 1189
2020
Q2 		$58K Buy
7,200
+5,200
+260% +$32.2K ﹤0.01% 1354
2020
Q1 		$8K Buy
+2,000
New +$7.56K ﹤0.01% 1954

Other funds holding TRIL

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
OPU
Omni Partners US Irvine, California $1.95B AUM
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
VI
Versor Investments New York $40.8M AUM 93.59% 1-Year Est. Return

Steward Partners Investment Advisory's TRIL Position: Q3 2021 in Review

Steward Partners Investment Advisory sold out of Trillium Therapeutics Inc. (TRIL) in Q3 2021, closing a stake of 2,500 shares — an estimated $24K sold.

Steward Partners Investment Advisory first reported a position in TRIL in Q1 2020 and held it in 6 quarters. The position peaked at $127K in Q4 2020. 182 funds tracked by Wall St. Rank hold TRIL as of Q3 2021.

  • Steward Partners Investment Advisory reported no remaining Trillium Therapeutics Inc. position as of Q3 2021 after selling out during the quarter.
  • Steward Partners Investment Advisory sold 2,500 Trillium Therapeutics Inc. shares in Q3 2021, an estimated $24K.
  • Steward Partners Investment Advisory first reported a position in Trillium Therapeutics Inc. in Q1 2020 and held it in 6 quarters.
  • Steward Partners Investment Advisory's Trillium Therapeutics Inc. position peaked at $127K in Q4 2020.
  • 182 funds tracked by Wall St. Rank held Trillium Therapeutics Inc. as of Q3 2021.

Based on Steward Partners Investment Advisory's 13F filing for Q3 2021, filed 12 Nov 2021.